More tools:Markets·Screener·Research·Chat

Myomo Inc. (MYO) Financial Statements

Myomo Inc.
SIC 3842 · ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES
FIGI BBG002B0JJW5
XASE · usd
1.33▼ 0.01 (-0.75%)
As of 2026-09-09
Valuation
Market Cap
Enterprise Value
Trailing P/E—
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close1.34
Day's Range1.31 – 1.37
52-Week Range0.61 – 1.89
Volume189.3K
Avg Volume662.6K
Share Statistics
Shares Outstanding
Employees195
ExchangeXASE
Listed2017-06-12
Share count as of July 31, 2026
Loading Income Statement…
Key questions about Myomo Inc. (MYO)
What is Myomo Inc.'s Market Cap?
Myomo Inc.'s Market Cap is $52.7M, based on as-reported figures from SEC (XBRL) filings.
What is Myomo Inc.'s Enterprise Value?
Myomo Inc.'s Enterprise Value is $51.0M, based on as-reported figures from SEC (XBRL) filings.
What is Myomo Inc.'s Price / Sales?
Myomo Inc.'s Price / Sales is 1.2×, based on as-reported figures from SEC (XBRL) filings.
What is Myomo Inc.'s EV / Revenue?
Myomo Inc.'s EV / Revenue is 1.2×, based on as-reported figures from SEC (XBRL) filings.
What is Myomo Inc.'s EV / EBITDA?
Myomo Inc.'s EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is Myomo Inc.'s Revenue (TTM)?
Myomo Inc.'s Revenue (TTM) is $43.3M, based on as-reported figures from SEC (XBRL) filings.
What is Myomo Inc.'s Net Income (TTM)?
Myomo Inc.'s Net Income (TTM) is -$14.5M, based on as-reported figures from SEC (XBRL) filings.
What is Myomo Inc.'s EBITDA?
Myomo Inc.'s EBITDA is -$10.8M, based on as-reported figures from SEC (XBRL) filings.
What is Myomo Inc.'s Diluted EPS (TTM)?
Myomo Inc.'s Diluted EPS (TTM) is -0.37, based on as-reported figures from SEC (XBRL) filings.
What is Myomo Inc.'s EBITDA Margin?
Myomo Inc.'s EBITDA Margin is -25.1%, based on as-reported figures from SEC (XBRL) filings.
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Revenue
YoY growth+21.3%+2.9%-5.9%+9.6%
Cost of revenue
Gross profit
% of revenue72.1%68.2%68.6%63.8%
Operating expenses:
Research and development
Selling, clinical and marketing
General and administrative
Total operating expenses
% of revenue91.4%99.5%93.0%98.7%
Loss from operations
% of revenue-19.3%-31.2%-24.4%-34.9%
Other expense (income), net
Interest expense (income), net
Change in fair value of derivatives liabilities———
Total Other (income), net
Loss before income taxes
Income Tax Expense
Net loss
% of revenue-34.4%-29.8%-33.6%-36.3%
Net loss per share attributable to common stockholders
Basic
Diluted